Shanghai MicroPort MedBot (Group) Co., Ltd. (2252.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive research, development, design, production, and distribution of surgical robotic systems, catering to markets in China and Europe. Their innovative product range features Toumai, a versatile laparoscopic surgical robot employed in urologic, gynecologic, thoracic, and general surgeries. They also provide DFVision, a 3D electronic laparoscope designed to improve visualization during abdominal, thoracic, and pelvic operations. For orthopedic procedures, the Honghu robot aids in knee and hip joint replacements, while the R-One system is specifically engineered for vascular interventions like coronary angioplasty. The iSR'obot, known as the Mona Lisa robotic system, specializes in transperineal prostate biopsies. Additionally, the company's offerings extend to specialized robots for spinal procedures, trans-bronchial diagnosis and treatment, TAVR (Transcatheter Aortic Valve Replacement), and automated needle-targeting systems for precise percutaneous lung biopsies and nephrolithotomy. Founded in 2014 and headquartered in Shanghai, China, the company functions as a subsidiary of MicroPort Scientific Corporation.

Industry: Medical - Devices
Sector: Healthcare
Headquarters: CN
CEO: Chao He
Listed since: Nov 2, 2021
Employees: 464

Market position

Day range

Current HK$22.50

HK$22.38HK$23.82

52-week range

Current HK$22.50

HK$18.76HK$35.34

Open: HK$23.80
Previous close: HK$23.76
Volume: 4M; 0.69× average
Average volume: 5.83M; Average daily volume
Market cap: 23.06B HKD
Beta: 1.46; Market reference 1
50-day average: HK$23.2148; -3.08% below average
200-day average: HK$25.3263; -11.16% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 22.08B CNY
P/E (TTM): -80.44×
P/B (TTM): 48.47×
P/S (TTM): 35.9×
EV / EBITDA: -228.04×
Earnings yield: -1.12%
Free cash flow yield: -0.17%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 48.38%
Operating margin: -42.69%
Net margin: -45.30%
Return on equity: -60.77%
Return on assets: -18.70%
Return on invested capital: -25.22%

Financial health

Debt / equity: 1.04×
Current ratio: 2.3×
Altman Z-score: 9.67
Piotroski F-score: 4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

551.07M CNY+114.22%

Operating income

−235.26M CNY+51.86%

Net income

−249.66M CNY+61.14%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	551.07M CNY	257.25M CNY	104.59M CNY	21.6M CNY	2.15M CNY
Cost of goods sold	284.45M CNY	171.03M CNY	89.9M CNY	15.04M CNY	1.23M CNY
Gross profit	266.62M CNY	86.22M CNY	14.69M CNY	6.56M CNY	919K CNY
Research and development	215.98M CNY	308.73M CNY	569.18M CNY	755.8M CNY	392.65M CNY
Selling, general, and administrative	249.25M CNY	263.22M CNY	364.79M CNY	354.51M CNY	230.16M CNY
Operating expenses	501.88M CNY	574.97M CNY	989.83M CNY	1.11B CNY	611.1M CNY
Interest income	6.83M CNY	2.2M CNY	8.69M CNY	26.65M CNY	22.07M CNY
Interest expense	19.67M CNY	21.51M CNY	18.41M CNY	11.13M CNY	5.29M CNY
Depreciation and amortization	74.15M CNY	61.04M CNY	111.76M CNY	42.48M CNY	35.37M CNY
Operating income	−235.26M CNY	−488.75M CNY	−975.14M CNY	−1.1B CNY	−551.7M CNY
Net income	−249.66M CNY	−642.41M CNY	−1.01B CNY	−1.14B CNY	−582.92M CNY